Harold J. Burstein

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Harold J. Burstein
Mar 25, 2025, 11:22 | Science
Harold J. Burstein: State-of-the-world assessment on breast cancer diagnosis and mortality
Harold J. Burstein, Breast Cancer Specialist and Professor at Harvard Medical School, shared an article by…
Mar 24, 2025, 13:48 | Blog
Paolo Tarantino: St. Gallen Consensus 2025 - 10 key votes
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "The…
Mar 16, 2025, 12:33 | Blog
Nagi El Saghir: Superb leadership by Harold J. Burstein of SGBCC2025 consensus session
Nagi El Saghir, Professor at American University of Beirut, shared a post on X: "Superb…
Dec 15, 2024, 19:48 | Blog
Harold J Burstein: Important presentation on anthracyclines and outcomes in TAILORx
Harold J Burstein, Breast Cancer Specialist and Professor at Harvard Medical School, shared on X:…
Dec 15, 2024, 03:31 | Insight
Stephanie Graff: Harold J. Burstein, sharing his self-proclaimed dreaded cross trial comparison
Stephanie Graff, Director of Breast Oncology at Brown University Health, shared a post on X:…
Dec 13, 2024, 05:49 | Insight
Highlights from Day 3 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 11, 2024, 19:12 | Insight
Highlights from Day 1 of SABCS 2024
The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…
Dec 11, 2024, 17:38 | Blog
SABCS24 Day 1 Highlights by Oncology Brothers
Oncology Brothers shared a post on X: "SABCS24 Day 1 Highlights CommunityOnc: FDA Oncology Reviews recent…
Nov 10, 2024, 03:29 | Insight
Harold J. Burstein: Anthracyclines in Early Breast Cancer - The Long Goodbye
Harold J. Burstein, Breast Cancer Specialist and Professor at Harvard Medical School, shared a recent…
Nov 4, 2024, 15:59 | Blog
Toni Choueiri: Vas Narasimhan on drug development, pre-clinical science, strategies and real world data
Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, shared…
Nov 2, 2024, 12:01 | Positive
Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024
As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…
Oct 27, 2024, 16:57 | Blog
Harold J. Burstein: 71% of US counties either lack an oncologist or lack an open cancer trials
Harold J. Burstein, Breast cancer specialist and Professor, Harvard Medical School, shared a post on…
Oct 8, 2024, 11:35 | Blog
Harold J. Burstein: Stressful Nobel Prize week thoughts
Harold J. Burstein, Breast Cancer Specialist and Professor at Dana-Farber Cancer Institute, shared a post on X:…
Sep 26, 2024, 16:19 | Blog
Antonio Giordano: Elevating value in cancer care
Antonio Giordano, President of Sbarro Health Research Organization, shared a post on X: ''Elevating value…
Sep 13, 2024, 07:45 | Blog
Harold J. Burstein: Important story on cancer toll among Latinos featuring Narjust Florez
Harold J. Burstein, Breast cancer specialist and Professor at Dana-Farber Cancer Institute, shared a post on…
Aug 29, 2024, 03:10 | Insight
ASCO Guideline Clinical Insights: Metastatic Hormone Receptor–Positive Breast Cancer
Yakup Ergün, Medical Oncologist at Bower Hospital, shared on X: "Targeted Therapies, Sequencing Strategies, and…
Jul 30, 2024, 13:03 | Insight
William Gibson: A general strategy for TP53 missense mutant cancers with prototype small molecules
Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared a…
Jul 29, 2024, 11:19 | Insight
Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…
Jul 20, 2024, 11:01 | Insight
Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial
Paolo Tarantino shared a post on LinkedIn about a paper titled "Adjuvant Trastuzumab Emtansine Versus…
Jul 14, 2024, 21:42 | Blog
Paolo Tarantino: Stellar Tumor Board session at the Harvard Medical School Breast Course
Paolo Tarantino shared a post on X: ''Stellar Tumor Board session at the Harvard Medical…
Jul 7, 2024, 04:49 | Insight
Harold J. Burstein: Important questions about 'getting to 2nd line therapy.'
Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared a…
Jul 1, 2024, 15:23 | Insight
Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial
Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…
Jun 21, 2024, 09:35 | Blog
Harold J. Burstein: Course on multidisciplinary care of breast cancer in early and late stages
Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared on…
May 3, 2024, 10:40 | Blog
Harold J. Burstein: USPSTF finally catches up in recommending mammograms starting at age 40
Harold J. Burstein, Breast cancer specialist and professor Dana Farber Cancer Institute and Harvard Medical School,…
Apr 22, 2024, 11:40 | Blog
Sara Tolaney: Very excited to have Aleix Prat as the Schlager Lecturer at the Harvard Breast Course in July!
Sara Tolaney shared a post by Aleix Prat, Co-Founder of Reveal Genomics, on X/Twitter, adding:…
Apr 15, 2024, 14:38 | Insight
New Paper Alert! Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response
Refining Treatment Approaches in Early Breast Cancer Patients with Pathologic Complete Response Authors: Carmine Valenza,…
Apr 1, 2024, 12:40 | Insight
Harold J. Burstein: 'Hallmarks of Cancer' paper gets an upgrade to v 3.0 in this issue of Cell
Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared on…
All: 27 Posts: 1 - 100
Special Coverage